Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia (AML/MDS/JMML)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01020539
Recruitment Status : Active, not recruiting
First Posted : November 25, 2009
Last Update Posted : July 27, 2017
Information provided by (Responsible Party):
Columbia University

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : March 2012
  Estimated Study Completion Date : March 2018